Mechanism of action and selectivity
Flucytosine is a classic prodrug. To exert an antifungal effect, the molecule must enter the pathogen cell and undergo activation.
Cellular uptake is mediated by a specific transport protein, cytosine permease. This step establishes the selectivity of action, as mammalian cell membranes lack this transporter.
Once inside the fungus, flucytosine is acted upon by the enzyme cytosine deaminase. This results in the formation of 5-fluorouracil (5-FU), a potent cellular poison and antimetabolite widely used in oncology. Human cells lack cytosine deaminase, making the direct formation of 5-fluorouracil in host tissues impossible.
How exactly does the fungus die?
The resulting 5-fluorouracil triggers two parallel pathways of cellular metabolism disruption, ultimately leading to cell division arrest (fungistatic effect).
- Blockade of DNA synthesis. The metabolite is converted into 5-fluoro-deoxyuridine monophosphate (5-FdUMP) with the participation of the enzyme ribonucleotide reductase. This substance binds and inhibits the enzyme thymidylate synthase. Without it, the conversion of deoxyuridine monophosphate (dUMP) to deoxythymidine monophosphate (dTMP) is impossible, causing an acute shortage of pyrimidines and a complete halt in DNA assembly.
- Synthesis of defective proteins. In the second pathway, 5-fluorouracil is phosphorylated to triphosphate (5-FUTP). This molecule is structurally similar to uracil and is deceptively incorporated into the RNA chain in its place. Based on this "faulty" RNA, aberrant proteins are synthesized that cannot perform their functions.
Pharmacokinetics and spectrum of activity
The drug can be administered both orally and intravenously. Due to its relatively short half-life, frequent administration is required—every 6 hours.
Flucytosine is characterized by a large volume of distribution and exceptionally well crosses histohematic barriers. It readily penetrates the blood-brain barrier: its level in cerebrospinal fluid ranges from 65 to 90% of the blood plasma concentration. It also accumulates in high concentrations in eye tissues and the urinary tract.
As monotherapy, the drug is effective in systemic candidiasis, cryptococcosis, and chromomycosis.
Why is combination with amphotericin B necessary?
In clinical practice, flucytosine is most commonly used not alone, but in combination with amphotericin B. This is a classic example of pharmacological synergism.
Amphotericin B damages the fungal plasma membrane. Through the resulting defects, flucytosine penetrates the cell much more easily and in larger quantities.
This combination offers several key advantages:
- Allows a reduced dosage of the toxic amphotericin B.
- Shortens the overall duration of the treatment course.
- Prevents the rapid development of resistance, which is inevitable with flucytosine monotherapy.
This combination is actively used to treat severe infections: cryptococcal meningoencephalitis and endocarditis, aspergillosis, and candidiasis involving the central nervous system and urinary tract.
Side effects and the toxicity paradox
Despite the fact that human cells are incapable of converting flucytosine into toxic 5-fluorouracil, the drug still causes side effects typical of cytostatics.
The reason lies in the intestinal microflora. Bacteria and fungi residing in the gastrointestinal tract possess the necessary enzymes. They metabolize part of the drug into 5-fluorouracil, which is then absorbed into the systemic circulation and poisons the host organism.
Main adverse reactions include:
- Hematological: bone marrow suppression (leukopenia, thrombocytopenia).
- Gastrointestinal: dyspeptic disorders (nausea, vomiting, diarrhea).
- Hepatobiliary: liver dysfunction.
- Dermatological: skin rashes.
The drug has an absolute contraindication—it must never be used during pregnancy.
Briefly: answers to topical questions
Which antifungal drugs, other than amphotericin B, is it advisable to combine with flucytosine?
According to the source, flucytosine can be combined with anidulafungin in refractory fungal infections.
To avoid confusing the enzymes: Permease — transports inside (transporter), Deaminase — activates (converts to 5-fluorouracil).
Class and exam questions
Why is flucytosine toxic to humans if we lack the enzyme for its activation?
Intestinal microflora possesses the necessary enzymes and converts part of the drug into toxic 5-fluorouracil, which is absorbed into the bloodstream and acts as a systemic cytostatic agent.
Why is flucytosine rarely used as monotherapy?
Fungal resistance to it develops very rapidly, which is why it is frequently combined with other drugs, such as amphotericin B.
How does the drug penetrate the cerebrospinal fluid?
It has a large volume of distribution and crosses the blood-brain barrier exceptionally well, achieving high concentrations in the CSF (up to 90% of plasma levels).
What else to study on this topic
- Biochemical cascade of the conversion of 5-fluorouracil into active phosphates
- The role of thymidylate synthase in DNA synthesis and the consequences of its blockade
- Features of the treatment of cryptococcal meningoencephalitis with combination therapy
- The effect of cytostatics on hematopoiesis using the side effects of 5-fluorouracil as an example
Master the entire topic in the «Pharmacology» course
This is a summary. The course covers everything tested in classes and exams.
- Complete study guide on "Flucytosine" and 5,304 more subject pages
- Assignments and quizzes after every topic — just like in a colloquium
- AI tutor answers questions on the topic anytime
- 116 video lessons on the subject
Other topics in the section "Antifungal agents"
Free video lessons: pharmacologyShort lessons with study notes — no registration required.
Prepared by WhiteCoat Pro faculty in accordance with the medical school curriculum. For educational purposes only.